<DOC>
	<DOCNO>NCT00820079</DOCNO>
	<brief_summary>Evaluation effect ADX10059 symptom control patient gastroesophageal reflux .</brief_summary>
	<brief_title>ADX10059 Monotherapy Patients With Gastroesophageal Reflux ( GERD )</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>diagnosis typical GERD well control standard clinical symptom control dose PPI treatment body mass index â‰¤32 kg/m2 exclusively atypical symptom GERD symptom show associated GERD erosive oesophagitis hiatus hernia &gt; 3 cm current diagnosis coexist psychiatric disease know clinically significant allergy know hypersensitivity drug pregnant breastfeed received sodium valproate topiramate within 30 day Screening history significant medical condition may affect safety patient preclude adequate participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Gastroesophageal reflux</keyword>
	<keyword>Heartburn</keyword>
	<keyword>Regurgitation</keyword>
</DOC>